Real-World Data (RWD) is the equivalent of field notes in anthropology: messy, unstructured, but full of valuable insights about how things work in the real world. Unlike randomized controlled trials (RCTs), which operate in the sterile confines of idealized conditions, RWD is collected from routine clinical care, patient registries,

Startups are curious beasts. They move fast, break things, raise millions, and yet remain spectacularly unable to define who is actually in charge of scheduling the Zoom calls. Titles abound—Founder, CEO, President, Principal Evangelist of Crypto-Enabled Omnichannel Innovation—and yet actual leadership is often thinner than a Series

Introduction: Platforms, Promise, and the VC Paradox Biotechnology has always been a high-stakes endeavor, with the odds stacked against any single drug making it to market. In recent years, a specific “platform company” model has risen to prominence. These are startups built around a versatile technology or modality – from

If you’ve been through business school, corporate training, or an executive retreat, chances are you’ve encountered the holy relics of management thinking: SWOT analyses, Porter’s Five Forces, RACI matrices, and SMART criteria. They’re taught with reverence, like ancient scriptures handed down from the mountaintop, even though

Strategy was once a noun. Then someone turned it into a 2x2 matrix and started charging €400/hour for it. In the beginning was the memo. Then came the workshop. And lo, the workshop begat the brainstorm, and the brainstorm begat The Framework™. And thus the modern consultant emerged, blinking

Foundations of a Gene Therapy Pioneer (1992–2010) bluebird bio began not as the vibrant name suggests, but as a modest startup called Genetix Pharmaceuticals in April 1992. Founded by two MIT researchers, Philippe Leboulch and Irving London, the company was grounded in a radical idea for its time: using

In the spirit of Thatcher—and with apologies to everyone who just spat out their ethically sourced oat milk—here’s a gentle reminder for anyone who’s ever outsourced conviction to a consultant: If you’re a founder relying on beautifully formatted advice to hide your own indecision, Thatcher

The biotechnology sector continuously faces significant funding challenges, balancing the enormous costs of clinical development with the necessity of minimizing dilution for early investors and founders. Recently, royalty financing has emerged as a strategic and expanding source of non-dilutive capital. It provides capital in exchange for future product revenues,

If there’s one thing that consistently frustrates me, it’s how pseudoscientific claims are dressed up as life-saving innovations. These misleading tactics often prey on our fears and uncertainties, particularly when we’re facing something as terrifying as cancer. Labels like “clinically proven,” “FDA registered,” or “vital essence”

Conflicting Narratives in a Growing Sector China’s early-stage biotech and drug development startups have been riding a seesaw of soaring optimism and sobering reality. On one side are upbeat proclamations of a biotech boom – thousands of new firms, gleaming research parks, and bold plans to rival Western pharma